Open AccessFOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Author(s) -
Angélique Vienot,
Hortense Chevalier,
Clément Bolognini,
Elisabeta Gherga,
Élodie Klajer,
Aurélia Meurisse,
Marine Jary,
Stéfano Kim,
Christelle d’Engremont,
Thierry Nguyen,
Fabien Calcagno,
Hamadi Almotlak,
Francine Fein,
Meher Nasri,
Syrine Abdeljaoued,
Anthony Turpin,
Christophe Borg,
Déwi Vernerey
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i3.332
Subject(s) - medicine , folfirinox , irinotecan , oxaliplatin , hazard ratio , gastroenterology , cohort , oncology , surgery , cancer , colorectal cancer , confidence interval
FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer.